


01997.043500



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
	:	Examiner: Stoica, Elly Gerald
VALGE-ARCHER et al.)	
	:	Group Art Unit: 1647
Application No.: 10/798,380)	
	:	Confirmation No.: 6499
Filed: March 12, 2004)	
	:	Customer No.: 05514
For: ANTIBODIES AGAINST HUMAN)	
IL-21 RECEPTOR AND USES	:	March 27, 2007
THEREFOR)	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

We also enclose a check for the required fee of \$180.00 to cover the Information Disclosure Statement under 37 C.F.R. 1.97(c)(2).


03/29/2007 AWONDAF1 00000002 10798380

03 FC:1806

180.00 OP

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Joseph P. Pieroni", written over a horizontal line.

Joseph P. Pieroni
Attorney for Applicants
Registration No.:53,469

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3800
Facsimile: (212) 218-2200

FORM PTO 1449 (modified)		ATTY DOCKET NO. 01997.043500	APPLICATION NO. 10/798,380
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		APPLICANT VALGE-ARCHER et al.	
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		FILING DATE March 12, 2004	GROUP 1647
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			
		Woodcock et al. "Three residues in the common $\gamma\beta$ chain of the human GM-CSF, IL-3 and IL-5 receptors are essential for GM-CSF and IL-5 but not IL-3 high affinity binding and interact with Glu21 of GM-CSF," EMBO J. 13:5176-85 (1994)	
		Mulhern et al. "The Solution Structure of the Cytokine-binding Domain of the Common β -Chain of the Receptors for Granulocyte-Macrophage Colony-stimulating Factor, Interleukin-3 and Interleukin-5," J. Mol. Biol. 297:989-1001 (2000)	
		Schimmenti et al. "Localization of an essential ligand binding determinant of the human erythropoietin receptor to a domain N-terminal to the WSXWS motif: implications for soluble receptor function," Exp. Hematol. 23:1341-46 (1995)	
		LaRosa et al. "Amino Terminus of the Interleukin-8 Receptor Is a Major Determinant of Receptor Subtype Specificity," J. Biol. Chem. 267:25402-06 (1992)	
		Imler et al. "Identification of three adjacent amino acids of interleukin-2 receptor β chain which control the affinity and the specificity of the interaction with interleukin-2," EMBO J. 11:2047-53 (1992)	
		Muyldermans "Single domain camel antibodies: current status," Rev. Mol. Biotech. 74:277-302 (2001)	
		Muyldermans et al. "Recognition of antigens by single domain antibody fragments: the superfluous luxury of paired domains," Trends Biochem. Sci. 26:230-35 (2001)	
		van den Beucken et al. "Building Novel Binding Ligands to B7.1 and B7.2 Based on Human Antibody Single Variable Light Chain Domains," J. Mol. Biol. 310:591-601 (2001)	
		Eilat et al. "The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus," Proc. Natl. Acad. Sci. U.S.A. 98:1148-53 (2001)	
		Davis et al. (1994), §20-3: "Site-directed mutagenesis," Basic Methods in Molecular Biology (pp. 738-744), 2 nd edition, Appleton & Lange, CT	
EXAMINER		DATE CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1